Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A 104-week, Multicenter, Open-label, Single-arm, Phase 3 Extension Trial Investigating the Long-term Safety and Efficacy of Glepaglutide in Adult Patients With Short Bowel Syndrome (SBS) Rolling Over From the EASE SBS 2 or 3 Trials

NCT07228403 is registered in ClinicalTrials.gov with Zealand Pharma as lead sponsor.

NCT NCT07228403
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07228403 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A 104-week, Multicenter, Open-label, Single-arm, Phase 3 Extension Trial Investigating the Long-term Safety and Efficacy of Glepaglutide in Adult Patients With Short Bowel Syndrome (SBS) Rolling Over From the EASE SBS 2 or 3 Trials
Lead sponsor
Zealand Pharma
Phase
Phase 3
Overall status
Active, not recruiting
Start date
December 11, 2025
Completion date
December 31, 2028
Enrollment
28 (actual)
Sites
16

Conditions

As the registry lists them; a condition with its own page is linked.

short bowel syndrome (sbs)